Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia.

Paterson A, Mockridge CI, Adams JE, Krysov S, Potter KN, Duncombe AS, Cook SJ, Stevenson FK, Packham G.

Blood. 2012 Feb 16;119(7):1726-36. doi: 10.1182/blood-2011-07-367417. Epub 2011 Dec 7.

2.

Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells.

Iglesias-Serret D, de Frias M, Santidrián AF, Coll-Mulet L, Cosialls AM, Barragán M, Domingo A, Gil J, Pons G.

Leukemia. 2007 Feb;21(2):281-7. Epub 2006 Dec 7.

PMID:
17151701
3.

Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.

Petlickovski A, Laurenti L, Li X, Marietti S, Chiusolo P, Sica S, Leone G, Efremov DG.

Blood. 2005 Jun 15;105(12):4820-7. Epub 2005 Feb 22.

4.

Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels.

Ewings KE, Wiggins CM, Cook SJ.

Cell Cycle. 2007 Sep 15;6(18):2236-40. Epub 2007 Jul 10. Review.

PMID:
17881896
5.

Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.

Melarangi T, Zhuang J, Lin K, Rockliffe N, Bosanquet AG, Oates M, Slupsky JR, Pettitt AR.

Cell Death Dis. 2012 Aug 16;3:e372. doi: 10.1038/cddis.2012.102.

6.

MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.

Pei XY, Dai Y, Tenorio S, Lu J, Harada H, Dent P, Grant S.

Blood. 2007 Sep 15;110(6):2092-101. Epub 2007 May 31.

7.

Mutant B-RAF mediates resistance to anoikis via Bad and Bim.

Boisvert-Adamo K, Aplin AE.

Oncogene. 2008 May 22;27(23):3301-12. doi: 10.1038/sj.onc.1211003. Epub 2008 Feb 4.

PMID:
18246127
8.

The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.

Rosich L, Saborit-Villarroya I, López-Guerra M, Xargay-Torrent S, Montraveta A, Aymerich M, Villamor N, Campo E, Pérez-Galán P, Roué G, Colomer D.

Haematologica. 2013 Nov;98(11):1739-47. doi: 10.3324/haematol.2013.088849. Epub 2013 Jul 12.

9.

The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.

Zhu HJ, Liu L, Fan L, Zhang LN, Fang C, Zou ZJ, Li JY, Xu W.

Leuk Lymphoma. 2013 Dec;54(12):2712-9. doi: 10.3109/10428194.2013.787613. Epub 2013 Apr 30.

PMID:
23517560
10.

Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.

Inoue S, Riley J, Gant TW, Dyer MJ, Cohen GM.

Leukemia. 2007 Aug;21(8):1773-82. Epub 2007 May 24.

PMID:
17525724
11.

Multisite phosphorylation regulates Bim stability and apoptotic activity.

Hübner A, Barrett T, Flavell RA, Davis RJ.

Mol Cell. 2008 May 23;30(4):415-25. doi: 10.1016/j.molcel.2008.03.025.

12.

MEK/ERK-mediated phosphorylation of Bim is required to ensure survival of T and B lymphocytes during mitogenic stimulation.

O'Reilly LA, Kruse EA, Puthalakath H, Kelly PN, Kaufmann T, Huang DC, Strasser A.

J Immunol. 2009 Jul 1;183(1):261-9. doi: 10.4049/jimmunol.0803853.

13.

Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.

Rubert J, Qian Z, Andraos R, Guthy DA, Radimerski T.

BMC Cancer. 2011 Jan 19;11:24. doi: 10.1186/1471-2407-11-24.

14.

c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.

Hallaert DY, Jaspers A, van Noesel CJ, van Oers MH, Kater AP, Eldering E.

Blood. 2008 Dec 15;112(13):5141-9. doi: 10.1182/blood-2008-03-146704. Epub 2008 Sep 16.

15.

AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells.

Santidrián AF, González-Gironès DM, Iglesias-Serret D, Coll-Mulet L, Cosialls AM, de Frias M, Campàs C, González-Barca E, Alonso E, Labi V, Viollet B, Benito A, Pons G, Villunger A, Gil J.

Blood. 2010 Oct 21;116(16):3023-32. doi: 10.1182/blood-2010-05-283960. Epub 2010 Jul 27.

16.

Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells.

Abutin RM, Chen J, Lung TK, Lloyd JA, Sawyer ST, Harada H.

Exp Hematol. 2009 Feb;37(2):151-8. doi: 10.1016/j.exphem.2008.10.008. Epub 2008 Dec 18.

17.

Alternative splicing of Bim and Erk-mediated Bim(EL) phosphorylation are dispensable for hematopoietic homeostasis in vivo.

Clybouw C, Merino D, Nebl T, Masson F, Robati M, O'Reilly L, Hübner A, Davis RJ, Strasser A, Bouillet P.

Cell Death Differ. 2012 Jun;19(6):1060-8. doi: 10.1038/cdd.2011.198. Epub 2012 Jan 13.

18.

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A.

J Clin Invest. 2007 Jan;117(1):112-21.

19.

Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function.

Qi XJ, Wildey GM, Howe PH.

J Biol Chem. 2006 Jan 13;281(2):813-23. Epub 2005 Nov 10.

20.

MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM.

Rambal AA, Panaguiton ZL, Kramer L, Grant S, Harada H.

Leukemia. 2009 Oct;23(10):1744-54. doi: 10.1038/leu.2009.80. Epub 2009 Apr 30.

Supplemental Content

Support Center